Dysfibrinogenemia-Potential Impact of Genotype on Thrombosis or Bleeding.


Journal

Seminars in thrombosis and hemostasis
ISSN: 1098-9064
Titre abrégé: Semin Thromb Hemost
Pays: United States
ID NLM: 0431155

Informations de publication

Date de publication:
Mar 2022
Historique:
pubmed: 15 7 2021
medline: 3 3 2022
entrez: 14 7 2021
Statut: ppublish

Résumé

The congenital dysfibrinogenemias, most often associated with bleeding disorders, encompass mutations in the amino-terminal end of fibrinogen α-chain consisting of Gly17-Pro18-Arg19-Val20, known as knob A, which is a critical site for fibrin polymerization. Here we review the studies reporting dysfibrinogenemia due to mutations affecting fibrinogen knob A and identified 29 papers. The number of reports on dysfibrinogenemias related to residues Gly17, Pro18, Arg19, and Val20 is 5, 4, 18, and 2, respectively. Dysfibrinogenemias related to residues Gly17, Pro18, and Val20 are exclusively associated with bleeding tendency. However, the clinical picture associated with dysfibrinogenemia related to residue Arg19 varies, with most patients suffering from bleeding tendencies, but also transitory ischemic attacks and retinal thrombosis may occur. The reason for this variation is unclear. To elaborate the genotype-phenotype associations further, we studied a Danish family with knob A-related dysfibrinogenemia caused by the Aα Arg19Gly (p.Arg19Gly) mutation using whole-exome sequencing and fibrin structure analysis. Our family is the first reported carrying the p.Arg19Gly mutation combined with one or more single nucleotide polymorphisms (SNP)s in

Identifiants

pubmed: 34261148
doi: 10.1055/s-0041-1730358
doi:

Substances chimiques

Fibrinogen 9001-32-5

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

161-173

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Mustafa Vakur Bor (MV)

Department of Clinical Biochemistry, University Hospital of Southern Denmark, Esbjerg, Denmark.

Søren Feddersen (S)

Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.

Inge Søkilde Pedersen (IS)

Department of Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.

Johannes Jakobsen Sidelmann (JJ)

Department of Clinical Biochemistry, University Hospital of Southern Denmark, Esbjerg, Denmark.
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark.

Søren Risom Kristensen (SR)

Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH